Lung Non-Small Cell Carcinoma Clinical Trials in Los Angeles, California

8 studies are recruiting for lung non-small cell carcinoma in Los Angeles, California right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial

   This phase III trial compares the effect of atezolizumab (or atezolizumab and recombinant human hyaluronidase) to standard observation for preventing cancer return after surgery (recurrence) in patients who have undergone a complete surgical removal (resection) of stage I non-small cell lung cancer…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Cedars-Sinai Medical Center, Los Angeles, California

   Locations

   70 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT07388524 on ClinicalTrials.gov

2. Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

   This phase III trial compares durvalumab to the usual approach (patient observation) after surgery for the treatment of patients with early-stage non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may in…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Cedars-Sinai Medical Center, Los Angeles, California

   Locations

   279 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT06498635 on ClinicalTrials.gov

3. Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

   This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immu…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Kaiser Permanente Los Angeles Medical Center, Los Angeles, California

   Locations

   1151 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT04267848 on ClinicalTrials.gov

4. A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment

   This phase II trial compares the effect of intensity-modulated post-operative radiation therapy (I²-PORT) followed by standard of care therapy (chemotherapy or immunotherapy) to standard of care therapy alone in treating patients with non-small cell lung cancer (NSCLC) who have remaining lymph node…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   USC / Norris Comprehensive Cancer Center, Los Angeles, California

   Locations

   97 in total

   Run by

   Alliance for Clinical Trials in Oncology

   See if you can join NCT07293247 on ClinicalTrials.gov

5. Gilteritinib for the Treatment of ALK NSCLC

   This phase I trial is studying the safety, side effects, and best dose of gilteritinib in treating patients with stage IV ALK positive non-small cell lung cancer (NSCLC) who have progressed on other treatments. While there are many approved targeted drugs for ALK NSCLC, resistance to these drugs fr…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Cedars-Sinai Medical Center, Los Angeles, California

   Locations

   3 in total

   Run by

   University of Michigan Rogel Cancer Center

   See if you can join NCT06225427 on ClinicalTrials.gov

6. Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung Cancer

   This phase II trial tests how well telisotuzumab vedotin and osimertinib works for the treatment of non small cell lung cancer that is growing, spreading, or getting worse (progressive) and for which no treatment is currently available (incurable). Telisotuzumab vedotin is a monoclonal antibody, ca…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California

   Run by

   Jonsson Comprehensive Cancer Center

   See if you can join NCT07323641 on ClinicalTrials.gov

7. Qualitative Study on Detection & Tx of NSCLC in Pts w/ a History of Alcohol or SUD

   This study will attempt to identify social facilitators and barriers to detection and treatment of non-small cell lung cancer in order to learn how a history of substance abuse or alcohol use impacts care for non-small cell lung cancer.

   Stage

   Not phased

   Ages

   18 and older

   Site

   Los Angeles General Medical Center, Los Angeles, California

   Locations

   2 in total

   Run by

   University of Southern California

   See if you can join NCT07186699 on ClinicalTrials.gov

8. Experiences w/ & Attitudes Towards Immune Chckpt Inhibitors in NSCLC Patients Single Center Survey Based Study

   This study evaluates patient satisfaction with receiving intravenous (IV) and/or subcutaneous (SC) immunotherapy and to assess patient preference for IV immunotherapy administration versus SC immunotherapy administration either at the hospital or at home.

   Stage

   Not phased

   Ages

   18 and older

   Site

   Los Angeles General Medical Center, Los Angeles, California

   Locations

   2 in total

   Run by

   University of Southern California

   See if you can join NCT07339254 on ClinicalTrials.gov